期刊
INFECTIOUS DISEASES
卷 53, 期 3, 页码 206-211出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/23744235.2020.1856921
关键词
Cefiderocol; Staphylococcus aureus; Pseudomonas Aeruginosa; surgical site infections; antimicrobial resistance; hospital acquired infections
Cefiderocol shows promise as an antibiotic for complicated infections caused by multidrug-resistant Gram-negative bacteria, including neurosurgical site infections.
Introduction Cefiderocol is a new siderophore cephalosporin designed to be active against extensively resistant Gram-negative bacteria; however, clinical studies are limited to complicated urinary tract infections, pneumonia, and intra-abdominal infections. To date, no data are available on neurosurgical site infections. Case presentation We present a case of a patient successfully cured with Cefiderocol for a neurosurgical site infection due to extensively resistant P. aeruginosa, who had failed a previous treatment based on combined antimicrobial therapy and right parietal bone excision. Conclusions Cefiderocol is a promising antibiotic for complicated infections due to multidrug resistant gram-negative bacteria.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据